<DOC>
	<DOCNO>NCT01842282</DOCNO>
	<brief_summary>This study involve use research drug , Amlexanox , treatment type 2 diabetes , insulin resistance , obesity non-alcoholic fatty liver disease ( NAFLD ) . Amlexanox take orally pill three time day . The investigator plan continue therapy period 12 week follow follow-up 4 week therapy end . The investigator evaluate change metabolic parameter ( e.g . blood cholesterol , liver function , insulin resistance ) body composition characteristic ( e.g . pattern fat distribution body ) . Seven eligible subject study also evaluate change liver disease liver biopsy .</brief_summary>
	<brief_title>Amlexanox Type 2 Diabetes Obesity</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Amlexanox</mesh_term>
	<criteria>≥ 18 year old baseline &lt; 60 year age . Is male , female childbearing potential , meet follow criterion female childbearing potential ( include perimenopausal woman menstrual period within one year ) : Not breastfeed . Negative pregnancy test result ( human chorionic gonadotropin , beta subunit [ βhCG ] ) baseline ( applicable hysterectomized female ) . Must practice willing continue practice appropriate birth control ( define method result low failure rate use consistently correctly , implant , injectables , oral contraceptive , intrauterine contraceptive device , sexual abstinence , tubal ligation , vasectomized partner ) entire duration study period . Has physicianconfirmed diabetes mellitus clear diagnosis per ADA criterion fast glucose &gt; 126 mg/dL HbA1c &gt; 6.4 % 2 hour GTT &gt; 200 mg/dL prediabetes fast glucose &gt; 100 mg/dL ( n= 8 ) BMI ≥27 &lt; 36 kg/m2 . On medication first line oral medication ( Metformin and/or DPP IV inhibitor ) treatment type 2 diabetes mellitus stable regimen &gt; 12 week . Alcohol consumption le 40 grams/week . A liver US confirm presence fatty infiltration liver . Is able read , understand sign U M IRBMED approve informed consent form ( ICF ) , communicate study physician study team , understand comply protocol requirement . On insulin , sulfonylurea injectables treatment type 2 diabetes Unable conduct home base glucose monitoring HbA1c &gt; 9.5 % Presence advance liver disease ( evidence abnormal synthetic function , abnormal PT albumin ) . Evidence etiologies viral hepatitis . Presence hematologic , bone marrow and/or abnormality . Presence hemoglobinopathy hematological abnormality interfere accurate measurement HbA1c Presence HIV infection . Inability give inform consent . Presence ESRD , type active cancer , &gt; class 2 congestive heart failure ( New York Heart Association Functional Classification System ) , base medical history physical examination . Active chronic infection know chronic osteomyelitis tb , etc . ( may transient ) . Creatinine &gt; 1.5 mg/dL Proliferative diabetic retinopathy , nonproliferative retinopathy allow Unable ambulate Clinically relevant CAD : history stent , CABG cardiologist confirm angina Any condition opinion investigator may impede successful data collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>diabetes mellitus type 2</keyword>
	<keyword>non alcoholic fatty liver disease</keyword>
	<keyword>obesity</keyword>
	<keyword>amlexanox</keyword>
</DOC>